Phase 1 Chronic Rhinosinusitis Trial, Completed NCT03979209 Sponsor: Rush University Medical Center Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial looked at three different doses of a nasal rinse containing mometasone (a steroid medication) — 1 mg, 2 mg, and 4 mg. The trial was measuring whether using this rinse continuously could affect levels of a hormone called cortisol in the blood. Cortisol is a natural hormone your body produces, and when people use steroid-based treatments, one thing researchers sometimes check is whether the body's own cortisol production is being reduced (known as "suppression"). A total of 16 people started and completed the trial — 2 in the 1 mg group and 14 in the 2 mg group. No participants were enrolled in the 4 mg group. The reported data shows that cortisol was measured in the morning — a standard time to check this hormone. For the 1 mg group, the average reported morning cortisol level was 17.35 micrograms per decilitre (mcg/dL), and for the 2 mg group it was 14.48 mcg/dL. No cortisol data was reported for the 4 mg group, as no participants were enrolled in that arm. No other outcome measures appear to have been submitted to ClinicalTrials.gov for this trial. It is worth noting that the 1 mg group included only 2 participants, which is a very small number, and no results for the 4 mg dose were available. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 1 Chronic Rhinosinusitis Trial, Completed

NCT03979209
Completed Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with Chronic Rhinosinusitis (long-term sinus inflammation), with or without nasal polyps
  • You have previously had sinus surgery using a camera (called endoscopic sinus surgery)
  • Your past surgery must have included removal of specific sinus tissue and widening of a sinus opening (confirm with trial site if unsure whether your surgery qualifies)

Who may not be able to join:

  • You have taken steroid tablets or injections (such as prednisone) within the last month
  • You have a condition where your adrenal glands do not work properly (adrenal insufficiency)
  • You have a liver disease or liver condition
  • You are a woman currently taking estrogen medication by mouth (oral estrogens)
  • You have a BMI (body mass index) over 38
  • You are currently pregnant
  • You are taking certain medications that affect a hormone system in the body called the HPA axis (confirm with trial site which medications apply)
  • You have been diagnosed with any of the following conditions: cystic fibrosis, sarcoidosis, problems with how your cilia (tiny hairs in the airway) move, widespread blood vessel inflammation, low levels of certain immune proteins (IgG or IgA deficiency), or a known problem with your pituitary or adrenal glands

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Rush University Medical Center
Registry
ClinicalTrials.gov
Start date
14 January 2019
Est. completion
22 June 2021

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Morning "AM" Serum Cortisol Level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov